Discovery & Development

The world is taking more interest in clinical trials. How are clinical trials adapting? Regeneron’s Bari Kowal keeps us updated.

Developing modified release formulations can be complex – but a translational pharmaceutics approach can smooth the path

Drug developers place their bets on the ROR-1 antigen in the battle against solid tumors.

Experts discuss the most exciting Alzheimer’s Disease treatment trends – and make bold predictions for the future

Following on from deaths attributed to contaminated medicines, here’s how the US Pharmacopeia is promoting testing for DEG and EG.

Progress in Alzheimer’s Disease research, but a cure will take time. Delaying it and disseminating that research may buy scientists the time they need

We ask about the story behind Nanoform and what nanotechnology could do for drug formulation.

Phesi CEO Gen Li discusses the impacts of the conflict between Russia and Ukraine on clinical trials

How – and why – we are tackling opioid use disorder with a monoclonal antibody

Veeva’s Richard Young looks back on breakthroughs in clinical trial technology and why the industry must continue to make trials more patient centric.